Kaken Pharmaceutical Co., Ltd. (TYO:4521)
3,980.00
-10.00 (-0.25%)
May 29, 2026, 3:30 PM JST
Kaken Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 44,713 | 54,093 | 50,625 | 59,561 | 61,025 |
Short-Term Investments | 5,992 | 15,992 | 14,699 | 14,699 | 13,599 |
Cash & Short-Term Investments | 50,705 | 70,085 | 65,324 | 74,260 | 74,624 |
Cash Growth | -27.65% | 7.29% | -12.03% | -0.49% | -3.47% |
Accounts Receivable | 19,378 | 21,178 | 23,744 | 19,268 | 20,260 |
Other Receivables | 3,370 | - | - | - | - |
Receivables | 22,748 | 21,178 | 23,744 | 19,268 | 20,260 |
Inventory | 19,115 | 19,020 | 17,167 | 15,563 | 14,980 |
Other Current Assets | 1,483 | 1,094 | 739 | 812 | 749 |
Total Current Assets | 94,051 | 111,377 | 106,974 | 109,903 | 110,613 |
Property, Plant & Equipment | 27,134 | 27,629 | 25,355 | 25,498 | 25,734 |
Long-Term Investments | 27,373 | 28,061 | 29,241 | 20,312 | 18,871 |
Goodwill | 5,399 | 14,035 | - | - | - |
Other Intangible Assets | 18,892 | 5,254 | 7,462 | 6,741 | 8,236 |
Long-Term Deferred Tax Assets | 5,367 | 4,065 | 2,590 | 3,873 | 1,725 |
Other Long-Term Assets | 1 | 1 | 1 | 1 | 2 |
Total Assets | 178,217 | 190,422 | 171,623 | 166,328 | 165,181 |
Accounts Payable | 7,566 | 8,322 | 7,099 | 6,219 | 5,939 |
Accrued Expenses | 2,590 | 2,385 | 1,639 | 1,561 | 1,394 |
Short-Term Debt | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 |
Current Income Taxes Payable | 4,558 | 13,596 | 4,222 | 7,828 | 5,979 |
Other Current Liabilities | 2,239 | 2,201 | 2,214 | 1,380 | 1,887 |
Total Current Liabilities | 20,803 | 30,354 | 19,024 | 20,838 | 19,049 |
Pension & Post-Retirement Benefits | 4,716 | 4,954 | 6,393 | 6,349 | 5,039 |
Long-Term Deferred Tax Liabilities | 4,405 | 1,514 | 1,947 | 1,771 | 2,229 |
Other Long-Term Liabilities | 675 | 966 | 505 | 535 | 540 |
Total Liabilities | 30,599 | 37,788 | 27,869 | 29,493 | 26,857 |
Common Stock | 23,853 | 23,853 | 23,853 | 23,853 | 23,853 |
Additional Paid-In Capital | 11,406 | 12,932 | 11,462 | 11,406 | 11,406 |
Retained Earnings | 125,625 | 135,242 | 128,506 | 126,135 | 126,347 |
Treasury Stock | -23,776 | -28,233 | -28,613 | -30,026 | -28,714 |
Comprehensive Income & Other | 10,510 | 8,840 | 8,546 | 4,889 | 4,854 |
Total Common Equity | 147,618 | 152,634 | 143,754 | 136,257 | 137,746 |
Minority Interest | - | - | - | 578 | 578 |
Shareholders' Equity | 147,618 | 152,634 | 143,754 | 136,835 | 138,324 |
Total Liabilities & Equity | 178,217 | 190,422 | 171,623 | 166,328 | 165,181 |
Total Debt | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 |
Net Cash (Debt) | 46,855 | 66,235 | 61,474 | 70,410 | 70,774 |
Net Cash Growth | -29.26% | 7.75% | -12.69% | -0.51% | -3.65% |
Net Cash Per Share | 1235.90 | 1735.63 | 1629.01 | 1874.05 | 1863.55 |
Filing Date Shares Outstanding | 37.87 | 37.87 | 37.87 | 37.47 | 37.79 |
Total Common Shares Outstanding | 37.87 | 38.4 | 37.87 | 37.47 | 37.82 |
Working Capital | 73,248 | 81,023 | 87,950 | 89,065 | 91,564 |
Book Value Per Share | 3898.11 | 3974.44 | 3796.01 | 3636.14 | 3642.30 |
Tangible Book Value | 123,327 | 133,345 | 136,292 | 129,516 | 129,510 |
Tangible Book Value Per Share | 3256.66 | 3472.18 | 3598.97 | 3456.25 | 3424.53 |